US market entry Calcivis has established a US headquarters in Milton, Massachusetts and is actively building a US commercial team, presenting a prime opportunity to engage dental distributors, large US clinics, and national hospital networks for partner onboarding and direct sales.

FDA approval leverage With FDA approval enabling clinicians in the United States to access the technology, sales efforts can focus on preventive dentistry adopters, care programs that emphasize real-time caries assessment, and value-based outcomes appealing to insurers and value-based care initiatives.

Revenue growth potential Current revenue is in the low single digits; combined with strategic US expansion, there is upside in selling to dental practices, groups, and potential licensing or OEM partnerships with larger medical device players seeking preventive diagnostic capabilities.

Leadership and governance signals Recent non-executive director appointments and a high-profile funding round from Scottish National Investment Bank indicate validation and momentum; leverage these milestones to approach strategic investors, partners, and potential distributors looking for credible growth stories.

Strategic market fit The technology supports preventive dentistry and patient engagement by providing chairside caries activity data; target evangelists such as dental schools, early-adopter clinics, and networks focused on minimally invasive dentistry to accelerate adoption and pilot programs.